An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01375478

ML25580

Details and patient eligibility

About

This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.

Enrollment: 197 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, over 18 years of age
• Moderate to severe rheumatoid arthritis
• RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form

Exclusion criteria

• Patients with rheumatic autoimmune disease other than rheumatoid arthritis
• Patients who are not willing to sign the informed consent form
• Patients who participate in interventional trials during the period of this observational study

Trial design

197 participants in 1 patient group

Cohort